The FDA has officially cleared the Dexcom G5 continuous glucose monitor to inform treatment decisions -- without the use of a fingerstick glucometer, other than for calibration. The G5 has been ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM ...
While GLP-1 agonists have grabbed investor attention for their potential as weight loss aids, these medicines also form a ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers.* Dexcom Smart Basal is FDA cleared and now the ...